🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07205523
Recruiting Observational

High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)

NCT07205523 · tracked via the Priya Life Science China tracker
Sponsor
Yigeng Cao,MD,PhD
Phase
Observational
Started
2023-09-01
Last updated
2025-10-03

Condition(s) studied

Hematopoietic Stem Cell Transplantation (HSCT)Acute Myeloid Leukemia (AML)Leukemias, Acute MyeloidMyeloid Leukemias, AcuteHemophiliaMyelodysplastic SyndromeMDSLymphomaLeukemiaAplastic AnemiaBleeding DisordersBone Marrow TransplantationMultiple MyelomaMyeloma, MultipleImmune Reconstitution

Study summary

The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau. Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, together with their donors, are systematically enrolled. The registry collects demographic, diagnostic, treatment, prognosis, and medical expense information, as well as biospecimens for future analyses. Historical data are incorporated, and prospective data collection is ongoing with long-term follow-up planned. The registry is designed as a sustainable research infrastructure to provide comprehensive data on disease incidence, treatment patterns, outcomes, and resource utilization in a high-altitude setting.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023. 2. Planned or actual hematopoietic stem cell transplantation (HSCT). 3. Provision of signed informed consent. Exclusion Criteria: 1. Inability to provide long-term follow-up data due to severe comorbidities or logistical reasons. 2. Substance abuse compromising adherence. 3. Any condition judged by investigators to jeopardize safety or compliance.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Affiliated Hospital of Qinghai University Xining Qinghai Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07205523 on ClinicalTrials.gov ↗ ← All trials in China